================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
Wednesday, April 28, 2004
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30975
(State of Formation) (Commission File Number)
911789357
(IRS Employer Identification Number)
12325 Emmet Street
Omaha, NE 68164
(Address of principal executive offices) (Zip Code)
(402) 452-5400
(Registrants' telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
================================================================================
Item 5. Other Events and Regulation FD Disclosure.
On Wednesday, April 28, 2004, the Company issued a press release
announcing it has agreed to provide additional quantities of modified nucleic
acid building block compounds to Geron Corporation under terms of multiple new
addendums to an existing Master Supply Agreement between the two companies. A
copy of the press release is filed herewith as Exhibit 99.1 and is incorporated
herein by reference.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release, dated Wednesday, April 28, 2004, announcing that the
Company has agreed to provide additional quantities of modified nucleic
acid building block compounds to Geron Corporation under terms of multiple
new addendums to an existing Master Supply Agreement between the two
companies.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TRANSGENOMIC, INC.
By /s/ Mitchell L. Murphy
-----------------------------------
Mitchell L. Murphy, Vice President,
Secretary & Treasurer
Wednesday, April 28, 2004
3